ImmuPharma (LON:IMM) Trading Up 30.2% - What's Next?

Key Points

• ImmuPharma's stock surged 30.2% on Monday, reaching a high of GBX 19.35 ($0.26) before closing at GBX 18.20 ($0.25) amid a trading volume increase of 365% compared to its average.
• The company reported an earnings per share of GBX (0.38) for the last quarter, with analysts predicting a significantly negative earnings per share of -339.0000022 for the current year.
• ImmuPharma focuses on peptide-based therapeutics for autoimmune diseases, with its lead program, Lupuzor™, targeting Lupus and showing potential for other conditions affecting the same mechanism.

ImmuPharma plc (LON:IMM - Get Free Report)'s share price rose 30.2% during trading on Monday . The stock traded as high as GBX 19.35 ($0.26) and last traded at GBX 18.20 ($0.25). Approximately 42,196,645 shares traded hands during trading, an increase of 407% from the average daily volume of 8,315,265 shares. The stock had previously closed at GBX 13.98 ($0.19).

ImmuPharma Stock Up 25.3%

The firm's 50-day moving average price is GBX 3.12 and its 200 day moving average price is GBX 2.91. The firm has a market cap of £87.51 million, a P/E ratio of -1,967.53 and a beta of 1.53.

ImmuPharma (LON:IMM - Get Free Report) last announced its earnings results on Wednesday, August 6th. The company reported GBX (0.38) earnings per share (EPS) for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 131.41%. On average, equities analysts predict that ImmuPharma plc will post -339.0000022 earnings per share for the current year.

ImmuPharma Company Profile

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.